Bill > SB1223

This bill proposes new requirements for labeling and disclosure of products in Missouri, specifically focusing on gene therapy and genetically modified products. The legislation defines key terms such as "cosmetic", "food", and "gene therapy product", and mandates that any product created or exposed to processes that could potentially act as a gene therapy must be labeled with "Potential Gene Therapy Product" or "Gene Therapy Product" depending on its known status. The bill also requires entities that produce, sell, or distribute products with the potential to infect or expose individuals to genetically modified material to provide comprehensive information about potential exposure pathways upon written request from a Missouri resident, with a response required within 21 days. Furthermore, the bill stipulates that any product that could potentially act as a medical intervention, vaccine, drug, or genetic modification must obtain fully informed consent from all individuals who could be exposed, which includes detailed information about benefits, risks, side effects, and potential impacts. The legislation aims to increase transparency and provide consumers with more comprehensive information about products that could have genetic or medical implications.

Health and Social Services

https://www.senate.mo.gov/26info/BTS_Web/Bill.aspx?SessionType=R&BillID=389